Brian M. Wolpin, Zev A. Wainberg, Ignacio Garrido-Laguna, Gulam Abbas Manji, Alexander I. Spira, Nilofer Saba Azad, Shubham Pant, Ying Zhang, Jessica Trang, Zeena Salman, Eileen M. O'Reilly. "Trial in progress: RASolute 302—A phase 3, multicenter, global, open-label, randomized study of daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor, versus standard of care chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).." Journal of Clinical Oncology (2025). https://doi.org/10.1200/jco.2025.43.16_suppl.tps4230